1. Navigating New Oral Treatment Algorithms in CLL

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Program Introduction

4. EMA Indications: BCR and Bcl-2 Inhibitors for Patients With CLL

5. Ibrutinib Efficacy in the Frontline Setting

6. Ibrutinib Efficacy in the Relapsed Setting

7. Safety of Ibrutinib: Long-Term Follow-Up

8. Ibrutinib Discontinuation: Clinical Considerations

9. Idelalisib Plus Rituximab in Relapsed CLL

10. Idelalisib Plus Ofatumumab in Relapsed CLL

11. Mechanism of Action: Ibrutinib, Idelalisib, and Venetoclax in CLL

12. Venetoclax Efficacy in the Relapsed Setting

13. Safety of Venetoclax: Minimizing Risk for TLS

14. Availability of Novel Oral Agents

15. Sequencing Options in Treating Relapsed CLL

16. Cytogenetic Testing for CLL

17. Complex Karyotype as Predictor of Outcomes

18. Treatment Options After Relapsing on Ibrutinib: Del(17p)

19. Treatment Options After Relapsing on Ibrutinib: No Adverse Deletions or Mutations

20. Revisiting Use of Chemoimmunotherapy in the Frontline Setting

21. Treating Relapsed CLL: Looking Ahead

22. Concluding Remarks

23. Abbreviations

24. Abbreviations (cont)

25. Abbreviations (cont)